Clinical Studies

Research Type Ethos Discovery De Novo Study Description Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second

Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.

A new cat diet has been shown to reduce body fat while maintaining lean muscle mass in cats. Accordingly, the following clinical study now seeks to determine if feeding this new diet without concurrent insulin therapy can induce insulin remission in cats with diabetes.

This clinical study seeks to determine if feeding the new diet in combination with insulin can improve glycemic control in dogs with moderately controlled diabetes.

This study will compare certain markers in the blood that are specific to cancer, but not found in healthy dogs, before and after surgical biopsy or surgical removal of a mass.

This study will compare markers in the blood that are specific to cancer but not found in healthy dogs, before and after treatment for cancer has begun.